Every now and again something new comes along which changes the world. Until recently, Novo Nordisk, a 100-year-old Danish pharmaceutical company and the original manufacturer of insulin for diabetes treatment, would have been unfamiliar to most people.
They are still at it. Launched in 2017, the Type II diabetes drug Ozempic now generates approximately $15 billion in annual revenue for the company, with this figure continuing to grow robustly… to view the full article, please click here.
